Key result
Acute coronary syndrome was associated with significantly higher hs-CRP and resistin levels and lower adiponectin levels compared to stable angina and healthy controls.
Why the study?
Does atorvastatin improve adipokine imbalance and inflammation in acute coronary syndrome models?
Cross-Sectional (n=586)
No
Does atorvastatin improve adipokine imbalance and inflammation in acute coronary syndrome models?
Acute coronary syndrome activates inflammation leading to an adipokine imbalance, which can be dose-dependently ameliorated by the anti-inflammatory effects of atorvastatin in preclinical models.
Answers are grounded in this paper and cite their sources.
Adipokine imbalance accompanies ACS in animal models; hypothesis-generating for atorvastatin effects, not yet clinically actionable.
Inflammation can be activated as a defensive response by the attack of acute coronary syndrome (ACS) for ischemic tissue injury. The aim of the present study was to investigate the impact of ACS-activated inflammation on adipokine imbalance and the effects of statins on the crosstalk between inflammation and adipokine imbalance during ACS. In this study, 586 subjects were categorized into: (1) control group; (2) SA (stable angina) group; and (3) ACS group. Circulating levels of hs-CRP, adiponectin and resistin were measured by ELISA. Furthermore, forty C57BL/6 mice were randomized into: sham, AMI, low-statin (atorvastatin, 2 mg/kg/day) and high-statin (atorvastatin, 20 mg/kg/day) group. After 3 weeks, AMI models were established by surgical coronary artery ligation. Circulating levels and adipose expressions of adiponectin and resistin were assessed in animals. Besides, we investigate the effects of atorvastatin on ox-LDL-induced adipokine imbalance in vitro. As a result, we found that ACS patients had higher hs-CRP and resistin levels and lower adiponectin levels. Our correlation analysis demonstrated hs-CRP concentrations were positively correlated with resistin but negatively with adiponectin levels in humans. Our animal findings indicated higher circulating hs-CRP and resistin levels and lower adiponectin levels in AMI mice. Atorvastatin pre-treatment dose-dependently decreased hs-CRP and resistin levels but increased adiponectin levels in mice. The consistent findings were observed about the adipose expressions of resistin and adiponectin in mice. In study in vitro, ox-LDL increased cellular resistin expressions and otherwise for adiponectin expressions, which dose-dependently reversed by the addition of atorvastatin. Therefore, our study indicates that the ACS attack activates inflammation leading to adipokine imbalance that can be ameliorated by anti-inflammation of atorvastatin.
No takes yet. Share an insight, caveat, or question.
Li et al. (2016) conducted a cross-sectional in Acute Coronary Syndrome (n=586). Acute Coronary Syndrome vs. Healthy controls was evaluated on Serum adiponectin levels (μg/ml) (p=<0.05). Acute coronary syndrome was associated with significantly higher hs-CRP and resistin levels and lower adiponectin levels compared to stable angina and healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: